NARI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NARI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inari Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-16.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-10.4 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Inari Medical's annualized ROC % for the quarter that ended in Mar. 2024 was -10.15%. Inari Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -55.48%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. Inari Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -0.36%.
The historical data trend for Inari Medical's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inari Medical Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EBIT | Get a 7-Day Free Trial | -0.27 | 14.92 | 10.98 | -25.89 | 4.44 |
Inari Medical Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EBIT | Get a 7-Day Free Trial | -1.15 | 3.07 | 5.63 | -3.11 | -16.01 |
For the Medical Devices subindustry, Inari Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Inari Medical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Inari Medical's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inari Medical (NAS:NARI) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Inari Medical's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:
ROC % (Q: Mar. 2024 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Dec. 2023 ) | + | Invested Capital (Q: Mar. 2024 )) | / count ) |
= | -32.38 * ( 1 - -50.44% ) | / | ( (484.136 | + | 476.156) | / 2 ) |
= | -48.712472 | / | 480.146 | |||
= | -10.15 % |
where
Invested Capital | (Q: Dec. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 674.235 | - | 74.647 | - | ( 115.452 | - | max(0, 76.339 | - | 235.563 | + | 115.452 | )) |
= | 484.136 |
Invested Capital | (Q: Mar. 2024 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 661.776 | - | 84.318 | - | ( 101.302 | - | max(0, 86.037 | - | 233.313 | + | 101.302 | )) |
= | 476.156 |
Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.
2. Joel Greenblatt's definition of Return on Capital:
Inari Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:
ROC (Joel Greenblatt) % | (Q: Mar. 2024 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Dec. 2023 | Q: Mar. 2024 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -64.036 | / | ( ( (69.336 + max(45.464, 0)) | + | (68.371 + max(47.693, 0)) ) | / | 2 ) |
= | -64.036 | / | ( ( 114.8 | + | 116.064 ) | / | 2 ) |
= | -64.036 | / | 115.432 | ||||
= | -55.48 % |
where Working Capital is:
Working Capital | (Q: Dec. 2023 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (70.119 | + | 42.9 | + | 7.092) | - | (74.647 | + | 0 | + | 0) |
= | 45.464 |
Working Capital | (Q: Mar. 2024 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (78.621 | + | 44.65 | + | 8.74) | - | (84.318 | + | 0 | + | 1.4210854715202E-14) |
= | 47.693 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
Inari Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:
Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Mar. 2024 ) |
= | -10.413 | / | 2854.539 | |
= | -0.36 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Inari Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
William Hoffman | director, officer: President and CEO | C/O INARI MEDICAL, INC., 9 PARKER, SUITE 100, IRVINE CA 92618 |
Mitch C. Hill, | officer: Chief Financial Officer | 1009 TENNYSON DRIVE, SOUTHLAKE TX 76902 |
Andrew Hykes | officer: Chief Operating Officer | C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618 |
Thomas Tu | officer: Chief Medical Officer | C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618 |
Donald B Milder | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Robert Keith Warner | director | C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
Catherine M. Szyman | director | C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614 |
Cynthia L Lucchese | director | 7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260 |
Mead Dana G Jr. | director | 2750 SAND HILL ROAD, MENLO PARK CA 94025 |
Rebecca Chambers | director | 3052 ORCHARD DR., SAN JOSE CA 95134 |
Jonathan D Root | director | 2735 SAND HILL ROAD, MENLO PARK CA 94025 |
Cooperatieve Gilde Healthcare Iv U.a. | 10 percent owner | NEWTONLANN 51, UTRECHT P7 3508AB |
Kirk G. Nielsen | director, 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Gilde Healthcare Iv Management B.v. | 10 percent owner | NEWTONLAAN 91, UTRECHT P7 3584 BP |
Gilde Healthcare Holding B.v. | 10 percent owner | NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB |
From GuruFocus
By Marketwired • 11-01-2023
By Tiesvg Tiesvg • 12-21-2022
By sperokesalga sperokesalga • 04-13-2023
By Marketwired • 08-24-2023
By Stock market mentor Stock market mentor • 01-10-2023
By sperokesalga sperokesalga • 05-02-2023
By GuruFocus Research • 10-11-2023
By GuruFocus Research • 10-19-2023
By Value_Insider Value_Insider • 11-02-2022
By Sydnee Gatewood • 02-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.